The Company´s cooperation partner, the Ludwig Institute for Cancer Research, New York carried out a proof-of-concept trial in collaboration at the Memorial Sloan-Kettering Cancer Center, New York. The trial examined whether REDECTANE® before the operation could provide an accurate prediction of whether or not the tumour was a clear cell renal cell carcinoma as determined by histopathology after the operation.
25 patients with suspected renal tumours were included in the study. They were diagnosed with PET/CT using REDECTANE® and these diagnoses were compared with histological findings regarding the renal tumour after surgery. 15 patients showed a high level of accumulation of REDECTANE®. A high accumulation of REDECTANE® could not be observed with the remaining ten patients. Clear cell RCC was confirmed with a specificity of 100% and a sensitivity of 94%.
REDECTANE® could determine whether the patient had clear cell renal cell carcinoma before surgery and the subsequent pathology. Therefore, REDECTANE® could significantly improve and simplify treatment planning for patients suspected of having renal cancer.